Prediabetes label clinically 'worthless'

Experts from University College London (UCL) and the Mayo Clinic in Minnesota in the US have said that giving people the prediabetes label has no clinical worth.

Their analysis, published in the British Medical Journal, states that current definitions for prediabetes risk "unnecessary" medicalisation and create "unsustainable burdens" for healthcare systems.

Treatments to reduce blood sugar only delayed the onset of type 2 diabetes by a few years, and the authors found no evidence of long-term health benefits, a UCL spokesman said.

"Prediabetes is an artificial category with virtually zero clinical relevance," said lead author John Yudkin, emeritus professor of medicine at UCL.

"There is no proven benefit of giving diabetes treatment drugs to people in this category before they develop diabetes, particularly since many of them would not go on to develop diabetes anyway.

"Sensibly, the World Health Organization, the National